The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Diagnosys sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Diagnosys is a medical device company that provides fully modular equipment for ophthalmic electrophysiology. The company’s product, Maculoscope is a focal ERG system that is the predicate device for most of the commercial ophthalmic testing equipment. The company is developing customizable platforms that are available for both human and animal testing. It also offers a variety of services to meet its customer’s needs including calibration, software, upgrades, and warranties. All its platforms provide the broadest stimulus range, highest test repeatability, most sensitive amplifiers, and most customizable software. It collaborates with researchers and clinicians to create and validate new test procedures for the benefit of patient care. It has offices in the US, Great Britain, and Ireland with distributors globally. Diagnosys is headquartered in Lowell, Massachusetts, the US.
The key metrics of Diagnosys related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Diagnosys is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Diagnosys.
For a detailed understanding of the performance of Diagnosys, buy the report here.